AU2020413633A1 - Compositions and methods for treating autoimmune diseases and cancers by targeting IGSF8 - Google Patents

Compositions and methods for treating autoimmune diseases and cancers by targeting IGSF8 Download PDF

Info

Publication number
AU2020413633A1
AU2020413633A1 AU2020413633A AU2020413633A AU2020413633A1 AU 2020413633 A1 AU2020413633 A1 AU 2020413633A1 AU 2020413633 A AU2020413633 A AU 2020413633A AU 2020413633 A AU2020413633 A AU 2020413633A AU 2020413633 A1 AU2020413633 A1 AU 2020413633A1
Authority
AU
Australia
Prior art keywords
igsf8
antibody
cancer
cell
antagonist
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
AU2020413633A
Other languages
English (en)
Inventor
Xihao HU
Xiaole LIU
Tengfei XIAO
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Shanghai Xunbaihui Biotechnology Co Ltd
Gv20 Therapeutics LLC
Original Assignee
Shanghai Xunbaihui Biotechnology Co Ltd
Gv20 Therapeutics LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shanghai Xunbaihui Biotechnology Co Ltd, Gv20 Therapeutics LLC filed Critical Shanghai Xunbaihui Biotechnology Co Ltd
Publication of AU2020413633A1 publication Critical patent/AU2020413633A1/en
Assigned to Shanghai Xunbaihui Biotechnology Co., Ltd., GV20 THERAPEUTICS LLC reassignment Shanghai Xunbaihui Biotechnology Co., Ltd. Request for Assignment Assignors: GV20 THERAPEUTICS LLC, SHANGHAI XBH BIOTECHNOLOGY CO., LTD.
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/002—Protozoa antigens
    • A61K39/005—Trypanosoma antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/32—Immunoglobulins specific features characterized by aspects of specificity or valency specific for a neo-epitope on a complex, e.g. antibody-antigen or ligand-receptor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Steroid Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
AU2020413633A 2019-12-25 2020-12-24 Compositions and methods for treating autoimmune diseases and cancers by targeting IGSF8 Pending AU2020413633A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CNPCT/CN2019/128294 2019-12-25
CN2019128294 2019-12-25
PCT/CN2020/139033 WO2021129744A1 (en) 2019-12-25 2020-12-24 Compositions and methods for treating autoimmune diseases and cancers by targeting igsf8

Publications (1)

Publication Number Publication Date
AU2020413633A1 true AU2020413633A1 (en) 2022-08-18

Family

ID=76575703

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2020413633A Pending AU2020413633A1 (en) 2019-12-25 2020-12-24 Compositions and methods for treating autoimmune diseases and cancers by targeting IGSF8

Country Status (11)

Country Link
US (1) US20230056288A1 (https=)
EP (1) EP4081253A4 (https=)
JP (1) JP2023512151A (https=)
KR (1) KR20220151161A (https=)
CN (1) CN115551549A (https=)
AU (1) AU2020413633A1 (https=)
CA (1) CA3165908A1 (https=)
IL (1) IL294280A (https=)
MX (1) MX2022008061A (https=)
TW (1) TW202135861A (https=)
WO (1) WO2021129744A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116724051A (zh) * 2020-08-10 2023-09-08 上海寻百会生物技术有限公司 用于通过靶向igsf8来治疗自身免疫性疾病和癌症的组合物和方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2604844A1 (en) * 2005-04-07 2006-10-19 Novartis Vaccines And Diagnostics, Inc. Cancer-related genes
WO2008034076A2 (en) * 2006-09-15 2008-03-20 The Johns Hopkins University Cyclophosphamide in combination with immune therapeutics
WO2012021840A2 (en) * 2010-08-13 2012-02-16 Biovest International, Inc. Materials and methods for designing autologous idiotype vaccines and treatment of b-cell malignancies
EP2824112B1 (en) * 2013-07-10 2016-12-21 Miltenyi Biotec GmbH Method for inducing proliferation of Natural Killer cells by mobile nanomatrices
EP3688011A4 (en) * 2017-10-25 2021-11-24 The Administrators Of The Tulane Educational Fund PEPTIDE COMPOSITIONS AND METHOD FOR THEIR USE
US12545728B2 (en) * 2019-02-04 2026-02-10 Lonza Sales Ag Treatment of cancer metastasis by targeting exosome proteins

Also Published As

Publication number Publication date
TW202135861A (zh) 2021-10-01
CA3165908A1 (en) 2021-07-01
JP2023512151A (ja) 2023-03-24
EP4081253A1 (en) 2022-11-02
CN115551549A (zh) 2022-12-30
KR20220151161A (ko) 2022-11-14
US20230056288A1 (en) 2023-02-23
EP4081253A4 (en) 2023-09-06
MX2022008061A (es) 2022-10-27
IL294280A (en) 2022-08-01
WO2021129744A1 (en) 2021-07-01

Similar Documents

Publication Publication Date Title
EP3283527B1 (en) Combination therapy for cancer
US20230416382A1 (en) Anti-c-c chemokine receptor 8 (ccr8) antibodies and methods of use thereof
JP2025108413A (ja) Ｐｓｇｌ－１アンタゴニスト及びその使用
WO2022033419A2 (en) Compositions and methods for treating autoimmune diseases and cancers by targeting igsf8
WO2021139682A1 (en) Anti-galectin-9 antibody and uses thereof
WO2021141907A1 (en) Anti-tnfr2 antibody and uses thereof
AU2022308421A1 (en) Anti-tnfr2 antibody and uses thereof
WO2021129744A1 (en) Compositions and methods for treating autoimmune diseases and cancers by targeting igsf8
US12617860B2 (en) Anti-TNFR2 antibody and uses thereof
RU2840501C1 (ru) Анти-галектин-9 антитело и его применение

Legal Events

Date Code Title Description
PC1 Assignment before grant (sect. 113)

Owner name: GV20 THERAPEUTICS LLC

Free format text: FORMER APPLICANT(S): SHANGHAI XBH BIOTECHNOLOGY CO., LTD.; GV20 THERAPEUTICS LLC

Owner name: SHANGHAI XUNBAIHUI BIOTECHNOLOGY CO., LTD.

Free format text: FORMER APPLICANT(S): SHANGHAI XBH BIOTECHNOLOGY CO., LTD.; GV20 THERAPEUTICS LLC